Sildenafil and tadalafil are separate active ingredients within the phosphodiesterase type 5 (PDE5) inhibitor class. They share the same broad molecular target and both enhance nitric-oxide-related cGMP signaling, but their pharmacokinetic profiles are markedly different. The clearest contrast is the persistence of systemic exposure: sildenafil has a terminal half-life of about 4 hours, while tadalafil has a mean terminal half-life of about 17.5 hours.
Their absorption profiles also differ. Under fasting conditions, sildenafil reaches maximum observed plasma concentration within approximately 30 to 120 minutes, with a median Tmax of about 60 minutes. Tadalafil reaches Cmax between approximately 30 minutes and 6 hours, with a median Tmax of about 2 hours. These PK values describe concentration timing and should not be confused with the exact beginning or duration of an individual clinical response.
The comparison also extends beyond PK. High-fat food slows sildenafil absorption but does not meaningfully alter tadalafil absorption, and current U.S. tadalafil labeling includes both as-needed and once-daily erectile-dysfunction frameworks as well as BPH-related indications. This page explains those differences neutrally rather than treating any single property as evidence that one medicine is universally preferable.
Sildenafil and tadalafil belong to the same PDE5 inhibitor drug class, but they are not different names, formulations or brands of one active ingredient. Each is a distinct molecule with its own concentration-time profile, metabolic characteristics and product labeling.
Their shared pharmacology explains why both appear in erectile-dysfunction treatment contexts. Their differences arise from drug-specific properties such as absorption timing, elimination rate, phosphodiesterase selectivity and the way each product is labeled for use.
For a broader view of where these two medicines fit alongside vardenafil and avanafil, see sildenafil vs other PDE5 inhibitors.
| Feature | Sildenafil | Tadalafil |
|---|---|---|
| Drug class | PDE5 inhibitor | PDE5 inhibitor |
| Primary target | PDE5 | PDE5 |
| Active ingredient | Sildenafil | Tadalafil |
| Fasting Tmax | 30–120 minutes; median about 60 minutes | 30 minutes–6 hours; median about 2 hours |
| Terminal half-life | About 4 hours | About 17.5 hours |
| Same molecule? | No | No |
Both sildenafil and tadalafil inhibit PDE5, an enzyme that participates in the breakdown of cyclic guanosine monophosphate, or cGMP. During sexual stimulation, nitric oxide signaling promotes cGMP formation, and reducing PDE5-mediated breakdown allows that signaling to persist longer.
The shared target means that the basic pharmacodynamic framework is similar for both medicines. Neither drug should be understood as creating the entire physiological signal independently; PDE5 inhibition modifies an existing NO-cGMP pathway.
The detailed sildenafil mechanism is covered on sildenafil PDE5 inhibition and the sildenafil NO-cGMP pathway.
| Mechanism Feature | Sildenafil | Tadalafil |
|---|---|---|
| Primary enzyme target | PDE5 | PDE5 |
| NO-cGMP pathway relevance | Yes | Yes |
| Reduces cGMP degradation | Yes | Yes |
| Identical molecular structure | No | No |
The two medicines differ substantially once their concentration-time profiles are examined. Sildenafil is rapidly absorbed, with maximum observed plasma concentrations occurring between approximately 30 and 120 minutes in the fasting state and a median Tmax of about one hour. Tadalafil has a broader peak-concentration window of approximately 30 minutes to 6 hours and a median Tmax of about 2 hours.
Peak timing is only one part of the difference. Sildenafil concentrations decline on a substantially shorter timescale, with a terminal half-life of about 4 hours, whereas tadalafil has a mean terminal half-life of approximately 17.5 hours. This difference produces much greater persistence of tadalafil exposure after a single administration.
These measurements describe pharmacokinetics rather than treatment quality. An earlier Tmax, a longer half-life or a larger exposure value cannot independently determine individual effectiveness. For the underlying terminology, see sildenafil pharmacokinetics.
| PK Characteristic | Sildenafil | Tadalafil |
|---|---|---|
| Fasting Tmax range | Approximately 30–120 minutes | Approximately 30 minutes–6 hours |
| Median Tmax | About 60 minutes | About 2 hours |
| Terminal half-life | About 4 hours | About 17.5 hours |
| Concentration persistence | Shorter | Substantially longer |
| Same PK profile? | No | No |
Tadalafil's median Tmax is later than sildenafil's, but this should not be interpreted to mean that its clinical response must begin later. Tmax is the time at which maximum observed plasma concentration occurs, while onset refers to the beginning of an observable pharmacodynamic effect.
A PDE5 inhibitor can begin producing a relevant pharmacological effect before Cmax is reached. The concentration required for a response can also differ among individuals, which is why comparing one Tmax number with another does not provide a complete onset comparison.
For sildenafil specifically, this distinction is explained on sildenafil Tmax and sildenafil onset.
| Timing Concept | Meaning |
|---|---|
| Tmax | Time at which the maximum observed plasma concentration occurs |
| Cmax | Magnitude of the maximum observed plasma concentration |
| Onset | Beginning of an observable pharmacodynamic or clinical effect |
| Same measurement? | No — Tmax and onset answer different questions |
Sildenafil ED tablet labeling is structured around as-needed administration before anticipated sexual activity. Current U.S. labeling generally centers administration around approximately one hour beforehand and allows a broader window extending from about 30 minutes to 4 hours before activity.
Tadalafil has a different regulatory framework. For as-needed erectile-dysfunction use, tadalafil is taken before anticipated sexual activity and clinical studies support improved erectile function compared with placebo for up to 36 hours after administration. Current labeling also includes a once-daily ED approach that is taken without regard to the timing of sexual activity.
These are product-label timing frameworks rather than universal predictions of individual onset or response duration. They show how the longer tadalafil exposure profile translates into a different way of describing product use, while the detailed prescribing decision remains outside the purpose of this comparison.
| Label Context | Sildenafil | Tadalafil |
|---|---|---|
| As-needed ED framework | Yes | Yes |
| General pre-activity timing language | Centered around about 1 hour; broader 30-minute-to-4-hour window | Taken prior to anticipated activity |
| Response demonstrated in labeling up to 36 hours | Not the sildenafil label framework | Yes for as-needed tadalafil |
| Once-daily ED framework | Not the standard ED-tablet label framework | Yes |
The sildenafil-versus-tadalafil comparison is often centered on duration, but duration should be described carefully. Sildenafil's systemic concentrations decline on a roughly 4-hour terminal half-life timescale, whereas tadalafil's approximately 17.5-hour half-life produces substantially longer drug persistence.
Current tadalafil labeling reports that as-needed tadalafil improved erectile function compared with placebo up to 36 hours following a dose. That labeled evidence is consistent with its longer concentration-time profile, but 36 hours should not be interpreted as a guaranteed continuous response or as a simple multiple of half-life.
The same principle applies to sildenafil: effect duration and plasma half-life are related but not identical concepts. For the sildenafil-specific distinction, see sildenafil duration and sildenafil half-life.
| Duration Dimension | Sildenafil | Tadalafil |
|---|---|---|
| Terminal half-life | About 4 hours | About 17.5 hours |
| Relative concentration persistence | Shorter | Longer |
| Up-to-36-hour labeled ED study context | No | Yes |
| Half-life equals exact effect duration? | No | No |
Food produces a measurable difference in sildenafil absorption. When sildenafil is administered with a high-fat meal, its absorption rate decreases: current labeling reports an average Tmax delay of approximately 60 minutes and an average Cmax reduction of about 29 percent compared with fasting administration.
Tadalafil behaves differently. Its current pharmacokinetic labeling states that the rate and extent of absorption are not influenced by food, which is why tadalafil tablets can be administered without regard to meals from a PK perspective.
This is a useful example of two drugs sharing the same pharmacological class while responding differently to gastrointestinal conditions. The sildenafil side of this comparison is covered in greater depth on sildenafil food effects.
| High-Fat Meal Effect | Sildenafil | Tadalafil |
|---|---|---|
| Absorption rate affected? | Yes | Not meaningfully |
| Mean Tmax change | Delayed about 60 minutes | No clinically meaningful food-related effect described |
| Mean Cmax change | Reduced about 29% | Rate and extent of absorption not influenced by food |
| Food-independent PK profile? | No | Yes in current labeling |
The difference between approximately 4 hours and 17.5 hours is one of the most important quantitative distinctions between sildenafil and tadalafil. Half-life describes the timescale of plasma concentration decline, so tadalafil remains in systemic circulation for considerably longer after a single administration.
A longer half-life also affects repeated administration. With once-daily tadalafil, steady-state plasma concentrations are reached within about five days and systemic exposure at steady state is higher than after a single administration. This creates an exposure framework that is different from an exclusively as-needed sildenafil ED tablet model.
Longer persistence should still not be interpreted as inherently better. It is a pharmacokinetic characteristic that changes treatment timing, accumulation and interaction context rather than a universal measure of clinical value.
| Half-Life Concept | Sildenafil | Tadalafil |
|---|---|---|
| Terminal half-life | About 4 hours | About 17.5 hours |
| Relative persistence | Shorter | Longer |
| Once-daily steady-state framework | Not the standard ED-tablet framework | Yes |
| Half-life alone determines response? | No | No |
Sildenafil has a reported mean absolute oral bioavailability of approximately 41 percent, with substantial variability across studied individuals. For tadalafil, absolute oral bioavailability has not been determined in current labeling, so there is no directly comparable absolute percentage to place beside sildenafil.
This illustrates an important limitation of pharmacokinetic comparison. AUC, Cmax and bioavailability describe exposure to a particular molecule; their absolute values cannot be used as simple scores to decide which different active ingredient is more effective.
Each medicine has its own potency, concentration-response relationship and pharmacodynamic profile. For more detail on these concepts, see sildenafil bioavailability and sildenafil exposure.
| Exposure Concept | Sildenafil | Tadalafil |
|---|---|---|
| Absolute oral bioavailability | Mean about 41% | Not determined in current labeling |
| AUC | Measures sildenafil systemic exposure | Measures tadalafil systemic exposure |
| Cmax | Drug-specific peak concentration | Drug-specific peak concentration |
| Higher exposure number means better drug? | No | No |
Both sildenafil and tadalafil rely substantially on hepatic CYP3A metabolism, which creates some overlap in their interaction framework. Strong modifiers of CYP3A activity can therefore alter systemic exposure to either medicine, although the size of the effect and the product-specific instructions are not interchangeable.
Sildenafil is metabolized predominantly through CYP3A, with CYP2C9 serving as a minor pathway. Its major circulating N-desmethyl metabolite remains pharmacologically active and contributes to the overall activity profile.
Tadalafil is predominantly metabolized by CYP3A4 to a catechol metabolite that undergoes further methylation and glucuronidation. Its major circulating metabolite is not expected to be pharmacologically active at observed concentrations. For sildenafil-specific metabolism, see sildenafil metabolism and sildenafil and CYP3A4.
| Metabolic Feature | Sildenafil | Tadalafil |
|---|---|---|
| Major enzyme pathway | CYP3A | CYP3A4 |
| Minor pathway | CYP2C9 | Not the defining secondary pathway in the same way |
| Major circulating metabolite active? | Yes, retains pharmacological activity | Not expected to be pharmacologically active at observed concentrations |
| CYP3A interaction context | Important | Important |
Sildenafil and tadalafil both target PDE5 selectively, but they interact differently with other phosphodiesterase family members in laboratory studies. This provides another example of how medicines can share a primary target while remaining pharmacologically distinct.
Sildenafil has measurable activity against PDE6, a phosphodiesterase involved in retinal phototransduction. Tadalafil is substantially more selective for PDE5 than PDE6 in its in-vitro labeling data, while tadalafil also interacts with PDE11 subtypes to a greater degree than many other phosphodiesterases.
These molecular selectivity findings should not be converted directly into a clinical ranking. In-vitro enzyme ratios describe target interactions under laboratory conditions and are only one component of the wider clinical pharmacology profile.
| Selectivity Dimension | Sildenafil | Tadalafil |
|---|---|---|
| Primary target | PDE5 | PDE5 |
| PDE6 interaction | More prominent relative to PDE5 than with tadalafil | Substantially lower relative activity than PDE5 |
| PDE11 interaction | Not a defining selectivity feature | Recognized in the in-vitro selectivity profile |
| Selectivity determines overall superiority? | No | No |
In the U.S. erectile-dysfunction context, both sildenafil and tadalafil are available as oral tablet products. Their broader regulatory contexts, however, are not identical. Sildenafil ED tablet labeling is focused on erectile dysfunction, while other sildenafil-containing products belong to separate indications such as pulmonary arterial hypertension.
Tadalafil tablet labeling includes erectile dysfunction, the signs and symptoms of benign prostatic hyperplasia, and combined ED/BPH indications. It also includes both as-needed and once-daily erectile-dysfunction treatment frameworks, giving tadalafil a different labeled-use structure from sildenafil ED tablets.
These distinctions belong to product labeling rather than to the shared PDE5 mechanism. For the broader sildenafil side, see sildenafil uses, sildenafil for erectile dysfunction and sildenafil formulations.
| Label / Product Feature | Sildenafil | Tadalafil |
|---|---|---|
| ED indication | Yes | Yes |
| As-needed ED framework | Yes | Yes |
| Once-daily ED framework | Not the standard sildenafil ED-tablet label framework | Yes |
| BPH indication | Not an ED sildenafil-tablet indication | Yes |
| Combined ED/BPH indication | No | Yes |
The approximately 4-hour versus 17.5-hour half-life difference is a reproducible population-level pharmacokinetic distinction, but it does not determine how every individual will respond. Absorption, metabolic activity, interacting medicines, organ function and pharmacodynamic sensitivity can all change the relationship between an administered medicine and its observed effects.
The same limitation applies to Tmax. A median of about 60 minutes for sildenafil and about 2 hours for tadalafil describes the center of studied distributions rather than a precise clock time that will occur in every person.
This variability is one reason a comparison page should describe population pharmacology without promising individualized timing. General sources of variability on the sildenafil side are covered on sildenafil PK variability.
| Variable | Potential Effect |
|---|---|
| Absorption | Can alter early concentration-time behavior |
| Food | Especially relevant to sildenafil absorption |
| Metabolic activity | Can alter systemic exposure and persistence |
| Interacting medicines | Can modify enzyme activity or pharmacodynamic effects |
| Individual sensitivity | Can alter response at a given exposure |
Sildenafil and tadalafil are best understood as related PDE5 inhibitors with a common target but very different concentration-persistence profiles. Sildenafil reaches its median plasma peak earlier and has a substantially shorter terminal half-life, while tadalafil persists much longer and has a distinct as-needed and once-daily labeling framework.
Food provides another clear contrast: a high-fat meal slows sildenafil absorption, whereas tadalafil absorption is not meaningfully influenced by food. Metabolism shows both similarity and difference, because both depend strongly on CYP3A but have different metabolites and persistence profiles.
None of these individual properties creates a universal better-versus-worse conclusion. Tmax, half-life, food effects, label structure and metabolite activity answer different questions, and individual treatment suitability requires clinical information beyond a pharmacology comparison.
| Comparison Question | Interpretation |
|---|---|
| Do they share the same drug class? | Yes. Both are PDE5 inhibitors. |
| Are they the same active ingredient? | No. |
| Which has the earlier median Tmax? | Sildenafil in the cited fasting PK data. |
| Which has the longer terminal half-life? | Tadalafil. |
| Does high-fat food slow sildenafil absorption? | Yes. |
| Does food meaningfully alter tadalafil absorption? | Not according to current labeling. |
| Does tadalafil have a once-daily ED framework? | Yes. |
| Do these properties establish a universal preferred treatment? | No. |
Both are PDE5 inhibitors, but their pharmacokinetic profiles differ substantially. Sildenafil has a terminal half-life of about 4 hours, while tadalafil has a mean terminal half-life of about 17.5 hours and a substantially longer concentration-persistence profile.
Under fasting conditions, sildenafil reaches maximum observed plasma concentration within approximately 30 to 120 minutes with a median of about 60 minutes. Tadalafil reaches Cmax between approximately 30 minutes and 6 hours with a median of about 2 hours.
No. Tmax measures the timing of peak plasma concentration, while clinical onset describes the beginning of an observable pharmacodynamic response. The two measurements are related but are not the same.
Tadalafil has the longer terminal half-life at approximately 17.5 hours, compared with about 4 hours for sildenafil.
Not in a simple one-to-one sense. Tadalafil labeling reports improved erectile function compared with placebo up to 36 hours after as-needed administration, but clinical duration is a pharmacodynamic concept and is not identical to plasma half-life.
A high-fat meal slows sildenafil absorption, with an average Tmax delay of about 60 minutes and an average Cmax reduction of about 29%. Current tadalafil labeling states that its rate and extent of absorption are not influenced by food.
Current U.S. tadalafil labeling includes both as-needed and once-daily erectile-dysfunction frameworks. Sildenafil ED tablet labeling uses an as-needed framework rather than an equivalent once-daily ED regimen.
They share the same broad mechanism of PDE5 inhibition and enhancement of NO-cGMP signaling, but they are different molecules with different pharmacokinetic and phosphodiesterase-selectivity profiles.
Both depend substantially on CYP3A metabolism, but their complete metabolic profiles differ. Sildenafil also has CYP2C9 involvement and an active major circulating metabolite, while tadalafil's major circulating metabolite is not expected to be pharmacologically active at observed concentrations.
No. High-fat food measurably slows sildenafil absorption, whereas current tadalafil labeling states that food does not influence its rate and extent of absorption.
Yes. Current U.S. tadalafil tablet labeling includes the signs and symptoms of benign prostatic hyperplasia and combined ED/BPH indications in addition to erectile dysfunction. Sildenafil ED tablet labeling is focused on erectile dysfunction, while other sildenafil products have separate labeled contexts.
The pharmacology comparison does not establish a universal preferred medicine. Sildenafil and tadalafil differ in peak timing, half-life, food effects, labeled-use framework and other properties, while individual suitability depends on clinical circumstances and product-specific prescribing information.